KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Adaptive Biotechnologies (ADPT) Debt to Equity: 2022-2025

Historic Debt to Equity for Adaptive Biotechnologies (ADPT) over the last 2 years, with Sep 2025 value amounting to $0.64.

  • Adaptive Biotechnologies' Debt to Equity rose 8.75% to $0.64 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.64, marking a year-over-year increase of 8.75%. This contributed to the annual value of $0.66 for FY2024, which is 55.19% up from last year.
  • Latest data reveals that Adaptive Biotechnologies reported Debt to Equity of $0.64 as of Q3 2025, which was down 13.23% from $0.74 recorded in Q2 2025.
  • Adaptive Biotechnologies' 5-year Debt to Equity high stood at $0.74 for Q2 2025, and its period low was $0.27 during Q4 2022.
  • For the 3-year period, Adaptive Biotechnologies' Debt to Equity averaged around $0.57, with its median value being $0.59 (2024).
  • Data for Adaptive Biotechnologies' Debt to Equity shows a peak YoY spiked of 65.11% (in 2024) over the last 5 years.
  • Quarterly analysis of 4 years shows Adaptive Biotechnologies' Debt to Equity stood at $0.27 in 2022, then surged by 56.87% to $0.42 in 2023, then soared by 55.19% to $0.66 in 2024, then increased by 8.75% to $0.64 in 2025.
  • Its last three reported values are $0.64 in Q3 2025, $0.74 for Q2 2025, and $0.70 during Q1 2025.